STOCK TITAN

Eloxx Pharmaceuticals Inc - ELOX STOCK NEWS

Welcome to our dedicated news page for Eloxx Pharmaceuticals (Ticker: ELOX), a resource for investors and traders seeking the latest updates and insights on Eloxx Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Eloxx Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Eloxx Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.07%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.95%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.38%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.1%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.67%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.92%
Tags
offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.59%
Tags
offering
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.59%
Tags
offering
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.8%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
clinical trial
Eloxx Pharmaceuticals Inc

Nasdaq:ELOX

ELOX Rankings

ELOX Stock Data

2.83M
2.78M
0.41%
18.53%
0.7%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Waltham

About ELOX

eloxx pharmaceuticals, inc. is a clinical-stage biopharmaceutical company developing novel rna-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. premature stop codons are point mutations that disrupt protein synthesis from messenger rna. as a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. these premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. read-through therapeutic development is focused on extending mrna half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. eloxx’s lead product candidate, elx-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. elx-02 is in the early stages of clin